摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

7-methoxy-N,N,1-trimethyl-9H-pyrido[3,4-b]indole-9-ethanamine | 101578-13-6

中文名称
——
中文别名
——
英文名称
7-methoxy-N,N,1-trimethyl-9H-pyrido[3,4-b]indole-9-ethanamine
英文别名
2-(7-methoxy-1-methyl-9H-pyrido[3,4-b]indol-9-yl)-N,N-dimethylethan-1-amine;2-(7-methoxy-1-methyl-9H-pyrido[3,4-b]indol-9-yl)-N,N-dimethyl ethanamine;[2-(7-methoxy-1-methyl-β-carbolin-9-yl)-ethyl]-dimethyl-amine;[2-(7-Methoxy-1-methyl-β-carbolin-9-yl)-aethyl]-dimethyl-amin;2-(7-methoxy-1-methylpyrido[3,4-b]indol-9-yl)-N,N-dimethylethanamine
7-methoxy-N,N,1-trimethyl-9H-pyrido[3,4-b]indole-9-ethanamine化学式
CAS
101578-13-6
化学式
C17H21N3O
mdl
——
分子量
283.373
InChiKey
MOPUAJCKFRRYRF-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    446.3±45.0 °C(predicted)
  • 密度:
    1.13±0.1 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    2.6
  • 重原子数:
    21
  • 可旋转键数:
    4
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.35
  • 拓扑面积:
    30.3
  • 氢给体数:
    0
  • 氢受体数:
    3

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    富马酸7-methoxy-N,N,1-trimethyl-9H-pyrido[3,4-b]indole-9-ethanamine丙酮 作用下, 以81 %的产率得到2-(7-methoxy-1-methyl-9H-pyrido[3,4-b]indol-9-yl)-N,N-dimethylethan-1-amine fumarate salt
    参考文献:
    名称:
    具有与阿尔茨海默病相关的治疗作用的心塑性 DYRK1A 抑制剂
    摘要:
    Tau蛋白病、神经元萎缩和心理障碍是阿尔茨海默病等神经退行性疾病的标志,目前缺乏能够纠正这些问题的有效临床治疗方法。为了解决这些未满足的需求,我们采用合理的药物设计,将DYRK1A抑制剂和isoDMT的药效团相结合,开发出心生DYRK1A抑制剂。通过这种方法,我们发现了一种非致幻性化合物,能够促进皮质神经元生长并抑制 tau 蛋白过度磷酸化,同时还具有减轻痴呆症的生物和心理症状的潜力。总之,我们的结果表明,DYRK1A 和精神质体原药效团的杂交代表了一种有前途的策略,用于识别可能解决痴呆症的认知以及行为和心理症状的化合物。
    DOI:
    10.1021/acs.jmedchem.3c01696
  • 作为产物:
    参考文献:
    名称:
    Sheljaskow et al., 1957, vol. 7, # 1, p. 29,32
    摘要:
    DOI:
点击查看最新优质反应信息

文献信息

  • ALKYL-AMINE HARMINE DERIVATIVES FOR PROMOTING BONE GROWTH
    申请人:OssiFi Inc.
    公开号:US20140288068A1
    公开(公告)日:2014-09-25
    In one aspect, the invention provides compounds of Formula I, and salts, hydrates and isomers thereof. In another aspect, the invention provides a method of promoting bone formation in a subject in need thereof by administering to the subject a therapeutically effective amount of a compound of Formula I, Formula II, or Formula III. The present invention also provides orthopedic and periodontal devices, as well as methods for the treatment of renal disease and cancer, using a compound of Formula I, Formula II, or Formula III.
    在一个方面,该发明提供了式I的化合物,以及其盐、合物和异构体。在另一个方面,该发明提供了一种通过向需要的受试者投予式I、式II或式III的化合物的治疗有效剂量来促进骨形成的方法。本发明还提供了骨科和牙周设备,以及使用式I、式II或式III的化合物治疗肾脏疾病和癌症的方法。
  • COMPOUNDS FOR BONE GROWTH
    申请人:OsteoQC, Inc
    公开号:US20170298059A1
    公开(公告)日:2017-10-19
    In one aspect, the invention provides compounds of Formula I, and salts, hydrates and isomers thereof. In another aspect, the invention provides a method of promoting bone formation in a subject in need thereof by administering to the subject a therapeutically effective amount of a compound of Formula I, Formula II, or Formula III. The present invention also provides orthopedic and periodontal devices, as well as methods for the treatment of renal disease and cancer, using a compound of Formula I, Formula II, or Formula III.
  • US9540365B2
    申请人:——
    公开号:US9540365B2
    公开(公告)日:2017-01-10
  • [EN] ALKYL-AMINE HARMINE DERIVATIVES FOR PROMOTING BONE GROWTH<br/>[FR] DÉRIVÉS D'ALKYL-AMINE HARMINE POUR FAVORISER LA CROISSANCE OSSEUSE
    申请人:OSSIFI INC
    公开号:WO2014153203A2
    公开(公告)日:2014-09-25
    In one aspect, the invention provides compounds of Formula I, and salts, hydrates and isomers thereof. In another aspect, the invention provides a method of promoting bone formation in a subject in need thereof by administering to the subject a therapeutically effective amount of a compound of Formula I, Formula II, or Formula III. The present invention also provides orthopedic and periodontal devices, as well as methods for the treatment of renal disease and cancer, using a compound of Formula I, Formula II, or Formula III.
查看更多